Stroke

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Phase 2 trials suggest LT3001 is safe in acute ischemic stroke and may boost day-90 recovery, paving the way for a global Phase 3.

Leaders from Brainomix provided commentary on data from ISC 2026, discussing how automated net water uptake from routine CT imaging may refine stroke severity assessment, thrombectomy selection, and system-level treatment equity.

High-dose constraint-induced therapy boosts arm function in toddlers after perinatal stroke, with gains lasting 6 months in phase 3 trial.

Andrew Russman, DO, director of Cleveland Clinic’s Comprehensive Stroke Center, provided an analysis of the phase 3 OCEANIC-STROKE data of asundexian in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack.

A professor of neurology from the University of Barcelona discussed the clinical implications of adding intra-arterial alteplase after thrombectomy in patients with Large-vessel occlusion (LVO) acute ischemic stroke at ISC 2026.

An interim DSMB review halted the rivaroxaban arm of the NIH-funded CAPTIVA trial in symptomatic intracranial atherosclerotic stroke due to increased safety events and futility compared with standard dual antiplatelet therapy.

Phase 3 data show tenecteplase before thrombectomy in late basilar artery stroke adds no functional benefit, with similar bleeding and mortality.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Shyam Prabhakaran, MD, MS. [LISTEN TIME: 15 minutes]

The professor of neurology at the University of Alabama at Birmingham talked about findings from a CREST-2 substudy presented at ISC 2026 showing that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. [WATCH TIME: 5 minutes]

A duo of experts at ISC 2026 discussed results from a clinical trial of high-dose, home-based constraint-induced movement therapy in infants with perinatal arterial ischemic stroke. [WATCH TIME: 5 minutes]

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, director of the JS Sonshine Center, shares her personal view on National Women Physician’s and why it’s important for clinicians and patients in the field.

In a recently published study, integrating prehospital GFAP measurements with established stroke scales significantly improved the accuracy of large vessel occlusion detection in patients with acute stroke.

The director of Cleveland Clinic's Gamme Knife Center and Head Section of Spine Tumors writes about how stereotactic radiosurgery has transformed modern neurology and neurosurgery

A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Neurology News Network for the week ending December 27, 2025. [WATCH TIME: 4 minutes]

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.